News/ News/ R&D AbbVie spies potential in Regenxbio eye disease gene therapy Phil Taylor AbbVie, gene therapy, ophthalmology, Regenxbio, RGX-314, wet AMD 0 Comment AbbVie has expanded its ophthalmology pipeline via a licensing deal with Regenxbio, paying $370 million upfront to get Share X AbbVie spies potential in Regenxbio eye disease gene therapy https://pharmaphorum.com/news/abbvie-spies-potential-in-regenxbio-eye-disease-gene-therapy/
AbbVie, gene therapy, ophthalmology, Regenxbio, RGX-314, wet AMD
0 Comment
